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Angin Y, Schwenk RW, Nergiz-Unal R, Hoebers N, Heemskerk JW,
Kuijpers MJ, Coumans WA, van Zandvoort MA, Bonen A, Neumann
D, Glatz JF, Luiken JJ. Calcium signaling recruits substrate transporters
GLUT4 and CD36 to the sarcolemma without increasing cardiac substrate
uptake. Am J Physiol Endocrinol Metab 307: E225–E236, 2014. First
published June 3, 2014; doi:10.1152/ajpendo.00655.2013.—Activation of
AMP-activated protein kinase (AMPK) in cardiomyocytes induces
translocation of glucose transporter GLUT4 and long-chain fatty acid
(LCFA) transporter CD36 from endosomal stores to the sarcolemma
to enhance glucose and LCFA uptake, respectively. Ca2/calmodulin-
activated kinase kinase- (CaMKK) has been positioned directly
upstream of AMPK. However, it is unknown whether acute increases
in [Ca2]i stimulate translocation of GLUT4 and CD36 and uptake of
glucose and LCFA or whether Ca2 signaling converges with AMPK
signaling to exert these actions. Therefore, we studied the interplay
between Ca2 and AMPK signaling in regulation of cardiomyocyte
substrate uptake. Exposure of primary cardiomyocytes to inhibitors or
activators of Ca2 signaling affected neither AMPK-Thr172 phosphor-
ylation nor basal and AMPK-mediated glucose and LCFA uptake.
Despite their lack of an effect on substrate uptake, Ca2 signaling
activators induced GLUT4 and CD36 translocation. In contrast,
AMPK activators stimulated GLUT4/CD36 translocation as well as
glucose/LCFA uptake. When cardiomyocytes were cotreated with
Ca2 signaling and AMPK activators, Ca2 signaling activators
further enhanced AMPK-induced glucose/LCFA uptake. In conclu-
sion, Ca2 signaling shows no involvement in AMPK-induced
GLUT4/CD36 translocation and substrate uptake but elicits trans-
porter translocation via a separate pathway requiring CaMKK/
CaMKs. Ca2-induced transporter translocation by itself appears to
be ineffective to increase substrate uptake but requires additional
AMPK activation to effectuate transporter translocation into increased
substrate uptake. Ca2-induced transporter translocation might be
crucial under excessive cardiac stress conditions that require supra-
physiological energy demands. Alternatively, Ca2 signaling might
prepare the heart for substrate uptake during physiological contraction
by inducing transporter translocation.
Ca2/calmodulin-activated kinases; AMP-activated protein kinase;
glucose transporter 4; CD36; cardiomyocytes
CARDIAC MUSCLE MEETS ITS ENERGY DEMANDS predominantly by
uptake of glucose (20–30%) and long-chain fatty acids
(LCFA; 60–70%) from the circulation. Whereas GLUT4 has
been established to be the major cardiac glucose transporter for
more than 20 years (50), the heart is known to express several
LCFA transporters, including CD36, fatty acid transport pro-
tein (FATP)1, and FATP6 (14). From these transporters, CD36
appeared to be quantitatively the most important one based on
studies using the specific CD36 inhibitor sulfo-N-succinimidy-
loleate (33) and using CD36-knockout mice (20). Additionally,
humans with CD36 deficiency show a nearly complete loss of
myocardial LCFA uptake (35). Hence, during the continuous
contractile activity of the heart, glucose and LCFA are taken up
mainly into cardiomyocytes via GLUT4 and CD36, respec-
tively (14, 31). We and others have shown that enhanced
cardiac contraction leads to the simultaneous translocation of
GLUT4 and CD36 from endosomal compartments to the sar-
colemma to increase substrate entry (7, 14, 32).
With respect to the signaling mechanisms involved in con-
traction-induced GLUT4 and CD36 translocation in cardiomy-
ocytes, there is solid evidence for the involvement of AMP-
activated protein kinase (AMPK), especially the AMPK2
isoform (21, 32). Following a rise in subcellular AMP, the
binding of AMP to AMPK makes this kinase conformationally
accessible for phosphorylation by an AMPK kinase at Thr172
so that it will become activated (15). AMP also protects AMPK
from dephosphorylation at Thr172, thus decelerating its deac-
tivation (15). In cardiomyocytes from LKB1-null mice, con-
traction-induced GLUT4 and CD36 translocation was abol-
ished, disclosing LKB1 as the responsible upstream kinase of
AMPK (21). Activation of AMPK results in a series of signal-
ing events, such as Akt substrate of 160 kDa (AS160) phos-
phorylation causing GLUT4 and CD36 translocation (39, 40)
and a consequential increase in substrate uptake. Additionally,
AMPK activation increases glucose and LCFA oxidation
through phosphorylation of glycolytic enzymes and of acetyl-
CoA carboxylase (ACC), respectively (27).
Besides regulating AMPK activity, the continuous contrac-
tions of the heart also regulate the reoccurring Ca2 transients.
A rise of the cytoplasmic Ca2 concentration ([Ca2]i) in each
excitation-contraction coupling of the heart and also of skeletal
muscle stimulates Ca2-dependent signaling events such as
activation of Ca2/calmodulin-dependent kinases through
binding of Ca2 to its carrier protein calmodulin. The binding
of the Ca2/calmodulin complex to the CaM domain of Ca2/
calmodulin-activated protein kinase kinases (CaMKKs) and of
Ca2/calmodulin-activated protein kinase (CaMK)II releases
the autoinhibition and leads to further activation of these
Ser/Thr protein kinases. Activated CaMKK phosphorylates
and activates its downstream target CaMKI. There are two
isoforms of CaMKK, of which only CaMKK is highly ex-
pressed in the heart. Under normal physiological conditions,
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[Ca2]i in the heart is finely regulated and the activity of
CaMKs regulated by protein phosphatases in concert with
[Ca2]i (3, 6, 8). Despite the fact that both CaMKK and
CaMKII are activated in response to a cytoplasmic Ca2 rise
via a Ca2/calmodulin-dependent manner, it has been shown in
skeletal muscle that both kinases also have autonomous activ-
ity (16, 38). Additionally, it was reported that exercise leads to
rapid activation and increased phosphorylation of CaMKII and
its downstream targets (37). However, the degree of autono-
mous activity of both CaMKKs and CaMKs, the speed of their
activation, and the duration of their active states have not yet
been reported for heart tissue.
Studies describing the role of Ca2 signaling in skeletal
muscle substrate uptake often have used caffeine to increase
[Ca2]i (1, 48). Specifically, it has been shown that caffeine
treatment induces CaMKK and CaMKII phosphorylation
concomitantly with increased glucose uptake. This caffeine-
induced glucose uptake was sensitive to pharmacological
CaMKK and CaMKII inhibition (48). Moreover, contraction-
induced glucose uptake was at least partly inhibited by
CaMKK and CaMKII inhibitors, which was indicative of a
role for both Ca2-activated kinases in contraction-induced
glucose uptake (48). Contraction-induced LCFA uptake also
appeared to be inhibited by CaMKK inhibition in skeletal
muscle (2), whereas CaMKII inhibition has not yet been
studied in this respect.
In contrast to skeletal muscle, information is lacking about
the roles of CaMKK and CaMKII in contraction-induced
substrate uptake in the heart, especially in relation to AMPK.
A possible bridge between Ca2 signaling and AMPK signal-
ing might be provided by CaMKK, because it is one of the
kinases known to have AMPK kinase activity in vitro and to
activate AMPK in mammalian cells deficient in LKB1 (25, 47).
Indeed, several studies in skeletal muscle indicate that
CaMKK and CaMKII stimulate muscle substrate uptake
through AMPK activation (2, 28). However, other data suggest
that this Ca2-induced signaling axis stimulates substrate up-
take independently of AMPK (46, 48). Therefore, the aim of
this study was to investigate the interrelation between AMPK,
CaMKs, and [Ca2]i in the regulation of transporter-mediated
substrate uptake into cardiomyocytes. To assess separately the
effects of [Ca2]i and of CaMKK/CaMKs on AMPK-medi-
ated substrate uptake, we used pharmacological agents to




Rats were maintained at the Experimental Animal Facility of
Maastricht University. All study protocols involving the rat experi-
ments were approved by the Animal Care and Use Committee of
Maastricht University and were performed according to the official
rules formulated in the Dutch law on care and use of experimental
animals, which are highly similar to those of the US National
Institutes of Health (NIH Publication No. 85-23, revised 1996).
Materials
2-Deoxy-D-[1-3H]glucose and [1-14C]palmitic acid were obtained
from GE Healthcare (Piscataway, NJ). Bovine serum albumin (BSA;
fraction V, essentially fatty acid free), laminin, phloretin, DMSO,
thapsigargin, A23187, STO-609, KN93, oligomycin, 5-amino-1--D-
ribofuranosyl-imidazole-4-carboxamide (AICAR), and adenine 9--
D-arabinofuranoside (ara-A) were obtained from Sigma Aldrich (St.
Louis, MO). Sulfo-NHS-LC-biotin and immobilized streptavidin were
from Perbio Science (Etten-Leur, The Netherlands). Compound C was
from Calbiochem (Radnor, PA). Fluo-4 acetoxy-methylester and plu-
ronic acid (F1420c1) were from Invitrogen (Bleiswijk, The Nether-
lands).
Antibodies
Antibodies were purchased as indicated: phospho-ACC (Ser79; no.
07-303) from Upstate (Billerica, MA); phospho-AMPK (Thr172; no.
2531), phospho-AS160 (Thr642; no. 4288), and phospho-CaMKII
(Thr286; no. 3361) from Cell Signaling Technology (Beverly, MA);
phospho-CaMKI (sc-28438-R) from Santa Cruz Biotechnology (Santa
Cruz, CA); caveolin-3 (no. 610420) from BD Transduction Labora-
tories (Franklin Lakes, NJ); anti-CD36 antibody (CRF D-2717) used
in 2-photon microscopic images from BD Pharmingen (Franklin
Lakes, NJ); and anti-GLUT4 (Ab 1346) used in Western Blotting
from Chemicon International (Billerica, MA). FITC-labeled rabbit
anti-mouse IgA secondary antibody was from from Rockland
Immunochemical (Gilbertsville, PA). The anti-CD36 antibody (no.
MO25) used in Western blotting was a gift from Dr. N. Tandon
(Bethesda, MD).
Isolation of Primary Rat Cardiomyocytes
Adult rat cardiomyocytes (Lewis rats; 200–250 g, 2–3 mo of age)
were isolated by using a Langendorff perfusion system according to
the procedure developed by Fischer et al. (12), as has been described
previously (33). This method yields mainly ventricular myocytes. A
modified Krebs-Henseleit bicarbonate (MKR) medium was stored at a
10-fold concentration and contained 1.17 M NaCl, 26 mM KCl, 12
mM KH2PO4, 12 mM MgSO4, 100 mM NaHCO3, and 100 mM
HEPES. Upon 10-fold dilution of the concentrated stock for daily use,
the MKR medium was adjusted to pH 7.55 and equilibrated with a
95% O2-5% CO2 gas phase at 37°C.
Experiments With Primary Cardiomyocytes
To recover from the isolation procedure, cardiomyocytes were
incubated for an additional 90 min in medium A (1 MKR medium
supplemented with 2% BSA, 2 mM D-glucose, and 1 mM CaCl2)
while rotating at room temperature (24°C). For substrate uptake
measurements 200,000 cells/condition were used, and for signaling
experiments 100,000 cells/condition were used. During these ex-
periments, cell suspensions were incubated with/without stimulators
and/or inhibitors of Ca2 and AMPK signaling in capped 20-ml glass
vials. The vials were placed in a 37°C water bath under continuous
shaking at 160 rpm.
Measurement of 2-Deoxy-[1-3H]glucose and [1-14C]palmitate
Uptake Rates Into Cardiomyocytes
To increase [Ca2]i and also activate CaMKs, cardiomyocytes
were exposed to 5 M A23187 or 5 M thapsigargin for 20 min. For
AMPK activation, cardiomyocytes were treated with either oligomy-
cin (5 M) or AICAR (1.5 mM) for 20 min or subjected to 4-Hz
electric field stimulation during the last 7 min of a 20-min total of
incubation time. For inhibition of CaMKs by STO-609 (5 M) or
KN93 (5 M), cardiomyocytes were preincubated for 20 min, where-
after either CaMKs or AMPK activating stimuli were added for an
additional 20 min. Subsequently, substrate uptake was measured by
the addition of 0.5 ml of a mixture of a 2-deoxy-[1-3H]glucose and
[1-14C]palmitate/BSA complex, as described previously (33). Five
minutes after the addition of the radiolabeled substrates, the uptake
reaction was stopped by transferring the cell contents to 15-ml Falcon
tubes containing ice-cold MKR buffer with 0.1% BSA and 0.2 mM
phloretin (stop solution). Cells then were washed two times for 2 min
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at 45 g in ice-cold stop solution, as described previously (33). The
radioactivity of the cell pellets was measured by scintillation counting.
Measurements of [Ca2]i
Freshly isolated cardiomyocytes were plated in laminin-coated
12-well plates in medium A. Cardiomyocytes were allowed to attach
to the bottom of each well for 90 min before loading with 5 M fluo-4
acetoxymethyl ester (AM) and 2 mg/ml pluronic F-127 for 30 min.
After a 15-min period to allow probe deesterification, the fluo-4-
loaded cells were washed three times with medium A. The washed
cells in the 12-well plate were subjected to Ca2 measurements by
pseudo-ratio fluorescence microscopic imaging using a filter
wheel-controlled Nikon Diaphot 200 microscope equipped with a
Hamamatsu EM-CCD digital camera and VitiTech (Sunderland, UK)
image control software (26). Fluorescence image recordings at 0.5 Hz
from microscopic fields (capturing for 20 ms) containing at least 15
cardiomyocytes were performed during the addition of thapsigargin,
A23187, or oligomycin (each at 5 M) at the indicated time periods.
Where indicated, cardiomyocytes were subjected to electric field
stimulation at a frequency of 4 Hz; image recording was at 0.24-s time
intervals. Fluo-4 fluorescence was analyzed per region of interest per
image, representing a single cell, and corrected for background (ad-
jacent regions of interest not representing a cell). Changes in fluores-
cence per region of interest were converted to pseudo-ratio values
F=  F/Fo, where F is the measured fluorescence value, Fo is the
average fluorescence level for 20 s under resting conditions, and F= is
the pseudo-ratio fluorescence level at any time (4).
Surface Detection of GLUT4 and CD36
Three distinct methods were used to assess cellular surface pres-
ence of GLUT4 and CD36.
Biotinylation method. The biotinylation technique was used to
separate plasma membrane proteins from subcellular proteins. After
isolation, cardiomyocytes were plated on laminin-coated (10 g/ml)
35-mm culture plates. After a 90-min attachment, cells were incubated
with stimuli and subsequently biotinylated with the cell-impermeable
reagent sulfo-NHS-LC-biotin in 1 MKR medium at a final concen-
tration of 1 mg/ml for 45 min at 4°C, as described previously (43).
Thereafter, cells were treated with ice-cold glycine (100 mM) in 1
MKR medium. After a brief wash with ice-cold 1 MKR medium,
cells were scraped in 300 l of lysis buffer [consisting of 50 mM
Tris·HCl, 150 mM NaCl, 1% (vol/vol) Igepal CA-630 (or NP-40), 5%
(wt/vol) sodium deoxycholate, 1% (wt/vol) SDS, 4% (vol/vol) com-
plete protease inhibitor cocktail, 5% PhosSTOP phosphatase inhibitor
cocktail]. The lysates were rotated for 1 h at 4°C and centrifuged for
10 min at 13,000 g at 4°C. Thirty microliters of supernatant was used
for detecting total protein samples with Western blotting, and 150 l
of supernatant was incubated overnight with streptavidin beads. Sam-
ples then were centrifuged for 2 min at 13,000 g at 4°C. Thereafter,
beads were washed twice with lysis buffer. The biotinylated proteins
were eluted by incubation of the streptavidin beads for 5 min at 95°C
in sample buffer (40% glycerol, 0.25 M Tris, 1 M DTT, bromophenol
blue). Samples were subjected to SDS polyacrylamide gel electropho-
resis, followed by Western blotting for the detection of GLUT4 and
C36.
Fractionation method. After recovery, cardiomyocytes were pre-
treated for 20 min with kinase inhibitors STO-609 and KN93 and
subsequently stimulated with the indicated agonist for 15 min. There-
after, cell suspensions were subjected to the fractionation procedure,
as described previously (32). GLUT4 and CD36 proteins were de-
tected by Western blotting.
Two-photon microscopy. Following a 10-min pretreatment with
either A23187, thapsigargin, or oligomycin, cells were labeled for 10
min with 2 g/ml (diluted in medium A) anti-CD36 antibody. Subse-
quently, FITC-labeled rabbit anti-mouse IgA secondary antibody
(Cend 1:500) was added to the cells. Finally, cardiomyocytes were
washed twice with medium A. Viable cardiomyocytes were imaged
using a Leica SP5 Multiphoton imaging platform (Leica Microsys-
tems). The excitation wavelength of the 140 fs-pulsed laser was 800
nm, whereas emission filters were optimized for FITC detection
(500–560 nm). Laser power was kept as low as possible to avoid
bleaching and photo damage. Because antibodies do not have access
to the cellular interior in these intact cardiomyocytes, only cell surface
CD36 will be stained. For quantification of the cell surface staining,
images were processed with ImageJ software (JAVA-based imaging
software from the National Institutes of Health). Cardiomyocytes
were kept at 37°C during incubations and imaging.
Statistics
Differences among the data obtained from five to eight experiments
are presented as means 	 SE. Statistical differences between groups
of observations were evaluated by unpaired Student’s t-test, one-way
ANOVA, and/or two-way ANOVA, depending on the groups com-
pared, by using statistical analysis software Prism 5 (GraphPad
Software). A P value 0.05 was considered statistically significant.
RESULTS
Testing the Potential of Thapsigargin and A23187 as
[Ca2]i Elevating Agents and STO-609 and KN93 as Ca2
Signaling Inhibitors in Cardiomyocytes
Fluorescent Ca2 indicators are suitable tools for studying
Ca2 transients in primary adult cardiomyocytes (23). In the
present study, cardiomyocytes isolated from adult rats were
adhered in 12-well plates and loaded with the Ca2 probe
fluo-4 to measure single-cell [Ca2]i transients by microscopic
fluorescence imaging. We used two agents with different
action mechanisms, i.e., the sarco/endoplasmic reticulum
Ca2-ATPase inhibitor thapsigargin and the Ca2 ionophore
A23187, to study the effects of increased [Ca2]i. Each of
these agents was used at 5 M, in agreement with previous
studies in myocytes (24, 44). Under resting conditions, in the
absence of electrical field stimulation, the majority of cells
displayed incidental Ca2 transients (Fig. 1), which paralleled
spontaneous contractions of the cells. In fluo-4-loaded cells
treated with the ATP synthase inhibitor oligomycin, the fre-
quency of the Ca2 transients increased threefold. In these
oligomycin-treated cells, as well as in cells exposed to 4-Hz
electrostimulation, levels of [Ca2]i fully restored to basal
levels in between each transient (Fig. 1). In contrast, stimula-
tion of the cells with either thapsigargin or A23187 provoked
marked and prolonged increases in [Ca2]I, not restoring to
baseline values within 5 min. At these concentrations, A23178
and thapsigargin did not affect short-term cell survival, as the
rod-shaped appearance of the cardiomyocytes was not altered
by these treatments (Fig. 1).
Compatible with their ability to increase [Ca2]i, thapsi-
gargin and A23187 enhanced phosphorylation of CaMKI (1.6-
and 2.2-fold, respectively) and of CaMKII (1.4- and 1.6-fold,
respectively) (Fig. 2A). A23187-induced CaMKI phosphoryla-
tion was significantly inhibited by the CaMKK inhibitor
STO-609 but not by the CaMKII inhibitor KN93 (Fig. 2A). In
contrast, A23187-induced CaMKII phosphorylation was sig-
nificantly inhibited by KN93 but not by STO-609 (Fig. 2A).
Both inhibitors were used at 5 M, in agreement with previous
cell studies (25, 45). We did not observe an increased phos-
phorylation of CaMKI or of CaMKII upon 7-min, 4-Hz stim-
ulation (Fig. 2B), which is in contrast to findings in skeletal
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muscle (1, 48). Additionally, treatment with oligomycin or
AICAR treatment did not increase phosphorylation of either
kinase (Fig. 2B).
We conclude that thapsigargin and A23187 increase [Ca2]i,
thereby activating both CaMKK- and CaMKII-dependent
signaling events in cardiomyocytes. Furthermore, Ca2 signal-
ing remains unchanged in response to oligomycin or AICAR,
indicating their specificity for AMPK activation in our cellular
model. Also, the inhibitors STO-609 and KN93 block their
intended target enzymes CaMKK and CaMKII, respectively.
Effects of Ca2 Signaling Inhibitors on AMPK Activation
and on AMPK-Mediated Substrate Uptake in
Cardiomyocytes
We investigated the roles of CaMKK and CaMKs in
AMPK activation and in AMPK-mediated substrate uptake
into cardiomyocytes. To activate AMPK in cardiomyocytes,
we used both a pharmacological approach (oligomycin or
AICAR) and a physiological approach (4-Hz electrostimula-
tion). Each of these treatments induced AMPK-Thr172 phos-
phorylation (7.4-, 6.2-, and 2.9 -fold, respectively) and, con-
comitantly, phosphorylation of AMPK’s major substrate ACC
at Ser97 (10-, 8-, and 3-fold, respectively) (Fig. 3A), in agree-
ment with our previous observations (32, 34). Correspond-
ingly, all three AMPK activators enhanced palmitate uptake
significantly (1.7-, 1.3-, and 1.4-fold, respectively). Addi-
tionally, oligomycin and 4-Hz electrostimulation enhanced
deoxyglucose uptake (2.2- and 1.4-fold, respectively),
whereas AICAR showed no effect (Fig. 3A). The inability of
AICAR to induce glucose uptake is in agreement with our
previous observations (10, 19, 33) and relates to the fact
that, next to AMPK activation, glucose uptake requires
Fig. 1. Thapsigargin and A23187 induce elevation of [Ca2]i in cardiomyocytes. For measurement of [Ca2]i, immobilized primary cardiomyocytes loaded with
fluo-4 were exposed to oligomycin (5 M), electrostimulation (4 Hz), thapsigargin (5 M), or A23187 (5 M) for the times indicated. Traces are from
representative cells; averaged traces are from 30 to 40 cells. At the concentrations used, A23187 or thapsigargin did not affect cell viability, as indicated by the
microscopical images taken at 0 and 15 min.*Vs. control (P 
 0.05).
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additional activation of protein kinase D1. As a result,
AICAR, which in contrast to oligomycin or 4-Hz stimula-
tion does not activate protein kinase D1, can only be used to
study AMPK-mediated LCFA uptake (10). Pretreatment of
cardiomyocytes with STO-609 or KN93 did not alter
AMPK-Thr172 and ACC-Ser97 phosphorylation induced by
all three AMPK-activating stimuli (Fig. 3A). Furthermore,
pretreatment with either of these inhibitors did not alter the
effect of each of the three AMPK-activating stimuli on
deoxyglucose or palmitate uptake (Fig. 3B).
In conclusion, Ca2 signaling does not appear to be involved
in either in AMPK activation or in AMPK-mediated substrate
uptake into cardiomyocytes.
Effects of Ca2-Elevating Stimuli on GLUT4 and CD36
Translocation in Cardiomyocytes
To investigate the effect of thapsigargin and A23187 on
GLUT4 and CD36 translocation, we used three independent
methods to monitor transporter translocation: cell surface
biotinylation, subcellular fractionation, and immunolabel-
ing. Immunolabeling of cell surface protein, in contrast to
the other methods, can be employed only for CD36 and not
for GLUT4 detection, because suitable GLUT4 antibodies
that are capable of recognizing the cell surface epitopes are
lacking at present. First, we examined GLUT4 and CD36
translocation via cell surface biotinylation with sulfo-NHS-
LC-biotin, which binds to free amino groups of extracellu-
larly exposed lysine residues. We have already applied this
method successfully to monitor insulin-induced CD36 trans-
location in Chinese hamster ovary cells (43). This method is
also suitable for detecting cell surface GLUT4, notwith-
standing that GLUT4 expresses only a single extracellular
lysine (at position 50). Accordingly, we (22) and others (11,
42) have shown that insulin stimulates the binding of sulfo-
NHS-LC-biotin to GLUT4. In the present study, oligomy-
cin, a well-established inducer of GLUT4 and CD36 trans-
location (32), was used as positive control to validate the
suitability of the cell surface biotinylation protocol and also
of the other methods to detect surface GLUT4 and CD36. As
shown in Fig. 4A, the biotinylation experiments showed that
oligomycin, thapsigargin, and A23187 enhanced sarcolem-
mal contents of GLUT4 (1.3-fold each) and CD36 (1.8-,
2.1-, and 1.9-fold, respectively) (Fig. 4A). This increase in
cell surface content of both transporters occurred in the
absence of changes in overall protein expression of GLUT4
and CD36 (Fig. 4A). Using subcellular fractionation, we
also detected an increased sarcolemmal content of GLUT4
(1.5-, 1.3-, and 1.4-fold, respectively) and of CD36 (1.5-,
1.7-, and 1.4-fold, respectively) upon treatment with each of
these stimuli (Fig. 4B). This method further demonstrated a
Fig. 2. Effects of the selected Ca2 signaling
activators and inhibitors as well as AMP-
activated protiein kinase (AMPK) activators
on phosphorylation of Ca2-dependent pro-
tein kinases. A: cardiomyocytes were prein-
cubated for 15 min in the absence [control
(C)] or presence of Ca2/calmodulin-depen-
dent protein kinase (CaMK) inhibitor STO-
609 (5 M) or CaMKII-specific inhibitor
KN93 (5 M) and then further treated with
thapsigargin (Tpg) or A23187 (A23) for an
additional 15 min. B: cardiomyocytes were
incubated for 15 min in the absence (C) or
presence of oligomycin (Oli; 5 M) or
5-amino-1--D-ribofuranosyl-imidazole-4-
carboxamide (AICAR; 1.5 mM); 4-Hz elec-
tric field stimulation was applied during the
last 7 min of overall incubations. At the end
of the incubations, cells were lysed, and
phosphorylation of CaMKI and CaMKII was
assessed by Western blotting. Caveolin-3
(Cav3) was used as a loading control. Values
are displayed as means 	 SE (n  5). *Vs.
control; #vs. A23187 (P 
 0.05).
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concomitantly decreased content of GLUT4 (by 40, 50, and
25%, respectively) and of CD36 (by 50, 70, and 65%,
respectively) from the low-density microsomal fraction that
represents intracellular membrane compartments (Fig. 4B).
Finally, immunodetection and microscopical visualization
of CD36 in intact cardiomyocytes clearly demonstrated
increased cell surface staining upon treatment with each
stimulus (Fig. 4C).
In conclusion, just as with oligomycin, the two applied
Ca2 raising agonists induce translocation of both GLUT4
and CD36 from intracellular membrane compartments to the
sarcolemma.
Effects of Ca2-Elevating Stimuli on Substrate Uptake Into
Cardiomyocytes
Based on the observation that thapsigargin and/or A23187
induce GLUT4 and CD36 translocation, we studied whether
transporter membrane localization results in increased glu-
cose and LCFA uptake rates, respectively. In agreement
with Fig. 3, A and B, oligomycin potently induced AMPK-
Thr172 and ACC-Ser97 phosphorylation and also phosphor-
ylation of AS160, another AMPK substrate (Fig. 5A), and
markedly enhanced deoxyglucose and palmitate uptake into
cardiomyocytes (Fig. 5B). However, thapsigargin and A23187
were without any effect on phosphorylation of AMPK and its
substrates ACC and AS160 and also did not affect deoxyglu-
cose and palmitate uptake (Fig. 5, A and B). Together, these
findings indicate that AMPK activation is not involved in
Ca2-induced GLUT4 and CD36 translocation and that Ca2-
induced translocation of both transporters as such is insuffi-
cient for increased glucose and/or LCFA uptake.
Apparently, Ca2-induced GLUT4 and CD36 translocation
did not effectuate into increased uptake. However, it is still
possible that coactivation of AMPK might be required to reveal
a stimulatory action of the [Ca2]i-raising agonists on glucose
and LCFA uptake. For this purpose, we studied the effects of
cotreatment of Ca2 signaling activators with AMPK activa-
tors on AMPK signaling and on deoxyglucose and palmitate
uptake. Thapsigargin and A23198, each unable to stimulate
AMPK signaling by themselves, were also unsuccessful in
further stimulating AMPK-Thr172, ACC-Ser97, and AS160-
Thr642 phosphorylation in oligomycin-treated cardiomyocytes
(Fig. 5A). However, remarkably, thapsigargin and A23187,
each unable to stimulate substrate uptake by themselves, en-
hanced deoxyglucose uptake significantly in the presence of
oligomycin cotreatment (1.4- and 1.3-fold, respectively) and
palmitate uptake in the presence of either oligomycin cotreat-
ment (each 1.3-fold) (Fig. 5B).
Fig. 3. Effects of STO-609 and KN93 on
AMPK activation and AMPK-mediated sub-
strate uptake into cardiomyocytes. Cardiomy-
ocytes were preincubated for 15 min in the
absence (C) or presence of STO-609 or KN93
and subsequently subjected to AMPK-acti-
vating stimuli (Oli; 5 M/15 min), AICAR (5
mM/15 min), and electric field stimulation (4
Hz/7 min). A: activation of AMPK and
acetyl-CoA carboxylase (ACC) was assessed
by Western blotting. B: uptake of 2-deoxy-[1-
3H]glucose and [1-14C]palmitate/BSA com-
plex (5 min) was determined as pelletable
radioactivity. Values are displayed as means 	
SE (n  5). *Vs. control (P 
 0.05).
E230 CALCIUM SIGNALING AND CARDIAC SUBSTRATE UPTAKE
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00655.2013 • www.ajpendo.org
Downloaded from journals.physiology.org/journal/ajpendo at Universiteit Maastricht (137.120.144.057) on September 15, 2021.
Fig. 4. Effects of [Ca2]i-elevating agents on
glucose transporter 4 (GLUT4) and CD36
translocation. Cardiomyocytes were preincu-
bated for 15 min in the absence (C) or pres-
ence of Tpg (5 M), A23 (5 M), or Oli (5
M, positive control). In selected experi-
ments, cardiomyocytes were pretreated with
STO-609 (5 M) or KN93 (5 M) for 15 min
prior to addition of the [Ca2]i-elevating
stimuli. Following these treatments, cardio-
myocytes were used for 3 different assays to
detect transporter translocation. A: biotinyla-
tion assay; GLUT4 and CD36 were detected
by Western blotting prior to biotinylation
(total) and after biotinylation (surface). Sig-
nals were quantified using Quantity-One soft-
ware (n  5). Representative blots are
shown. B: fractionation method; in the col-
lected plasma membrane and low-density mi-
crosomal fractions, GLUT4 and CD36 were
detected by Western blotting and quantified
(n  5). Representative blots are shown. C:
2-photon microscopy; CD36 was detected
upon FITC labeling. Quantification of the
CD36 signal was performed using ImageJ
software (n  5). Representative microscop-
ical images are shown. Values are displayed
as means 	 SE. *Vs. C; #vs. A23 (P 
 0.05).
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Effects of AMPK Inhibitors on Substrate Uptake Into
Cardiomyocytes Treated With Ca2 and AMPK Activators
To determine whether A23187-stimulated substrate uptake
in the presence of AMPK coactivation was dependent on this
AMPK coactivation and not due to off-target actions of the
used AMPK activators, we incubated cardiomyocytes with
established AMPK inhibitors, i.e., compound C and Ara-A. In
the absence of these inhibitors, AICAR stimulated palmitate
uptake 1.3-fold, and A23187 further stimulated palmitate up-
take 1.3-fold, bringing the combined activation to 1.6-fold
(Fig. 6A). As expected, each of these AMPK inhibitors suc-
cessfully inhibited AICAR-induced AMPK-Thr172 and ACC-
Ser97 phosphorylation (Fig. 6B). Although compound C and
Ara-A did not alter basal palmitate uptake, each agent com-
pletely inhibited AICAR-induced palmitate uptake (Fig. 6A).
Furthermore, each agent completely inhibited A23187-stimu-
lated palmitate uptake in the presence of AICAR cotreatment
(Fig. 6A).
In conclusion, the ability of A23187 to increase deoxyglu-
cose and palmitate uptake into cardiomyocytes in the presence
of AMPK activators indicates that Ca2-induced transporter
translocation requires AMPK coactivation for effectuating
such translocation into enhanced substrate uptake.
DISCUSSION
The aim of this study was to investigate the interrelation
between [Ca2]i, CaMKK/CaMKs, and AMPK in the short-
term regulation of substrate uptake into the heart. This short-
term regulation is mediated by translocation of GLUT4 and
CD36 to the cell surface. The major novel findings of this study
are as follows: 1) Ca2 signaling is not involved either in
AMPK activation or in AMPK-mediated substrate uptake; 2)
activation of Ca2 signaling, similarly to AMPK signaling,
stimulates translocation of GLUT4 and CD36 from endosomes
to the sarcolemma; 3) in contrast, activation of Ca2 signaling
does not stimulate glucose or LCFA uptake, whereas AMPK
signaling does; and finally, 4) Ca2-induced translocation of
GLUT4 and/or CD36 can result in enhanced substrate uptake
when accompanied with AMPK activation.
Together, these findings propose that Ca2-induced trans-
porter translocation may help to recruit an additional quantity
of substrate transporters to the sarcolemma to have these
available to respond rapidly to conditions that require supra-
physiological energy demands.
Ca2 Signaling is Not Involved in Either AMPK Activation
or AMPK-Mediated Substrate Uptake
In skeletal muscle, activation of Ca2 signaling induces
AMPK activation, and CaMKK appears to be involved in
contraction-induced AMPK activation (2, 28). In contrast,
in our cardiomyocyte studies the [Ca2]i-increasing stimuli
A23187 and thapsigargin did not alter AMPK activation.
Moreover, neither STO-609 nor KN93 affected contraction-
induced AMPK activation or AMPK activation by AICAR or
oligomycin, thus excluding a role for CaMKK or CaMKII in
the regulation of AMPK signaling in the heart. The inability of
CaMKII to activate AMPK in cardiomyocytes is in agreement
with previous work in skeletal muscle (48). However, the lack
Fig. 5. Effects of [Ca2]i-increasing agents
on AMPK activation and substrate uptake
into primary cardiomyocytes. Cardiomyo-
cytes were incubated for 15 min in the ab-
sence (C) or presence of Tpg (5 M), A23 (5
M), or Oli (5 M). A: phosphorylation of
AMPK, ACC, and Akt substrate of 160 kDa
(AS160) was assessed by Western blotting.
B: uptake of 2-deoxy-[1-3H]glucose and [1-
14C]palmitate (5 min) was determined as pel-
letable radioactivity. Values are displayed as
means 	 SE (n  5). *Vs. control (P 
 0.05).
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of involvement of CaMKK in AMPK activation in cardio-
myocytes points toward differences in the regulation of AMPK
between heart and skeletal muscle.
With respect to the regulation of substrate uptake, we ob-
served that in cardiomyocytes AMPK-activating stimuli (in-
cluding contraction) enhance GLUT4 and CD36 translocation,
as well as glucose and LCFA uptake, in agreement with our
previous studies (9, 21). The inability of STO-609 or KN93 to
inhibit AMPK-mediated substrate uptake matches the inability
of both inhibitors to affect AMPK signaling and excludes the
involvement of CaMKK or CaMKII herein. These findings
are in line with our previous observations in cardiomyocytes
from LKB1-knockout mice, in which AMPK-mediated in-
creases in glucose and LCFA uptake were lost entirely (21),
and therefore, they provide further evidence that LKB1, and
not CaMKK, is the AMPK-activating kinase involved in the
contraction-induced regulation of cardiac substrate uptake.
Activation of Ca2 Signaling Stimulates Translocation of
GLUT4 and CD36
Although the effect of [Ca2]i-increasing stimuli on glucose
transport in skeletal muscle has been a topic of several studies
(28, 46, 48), only few studies have shown GLUT4 transloca-
tion upon treatment with [Ca2]i-increasing stimuli (e.g., see
Ref. 2). To our knowledge, no studies have shown that an
elevation in [Ca2]i induces GLUT4 translocation in cardio-
myocytes. The present study fills this gap, because cell surface
biotinylation as well as subcellular fractionation reveal that
both A23187 and thapsigargin induce GLUT4 translocation.
Reports on a relationship between Ca2 signaling and CD36
translocation are limited to observations that caffeine induces
CD36 translocation in skeletal muscle (2, 30), whereas no
studies have been undertaken with respect to the heart. How-
ever, caffeine stimulates both Ca2 signaling and AMPK
signaling simultaneously, and therefore, this agent is not suited
to study the effects of Ca2 signaling separated from AMPK
signaling. Each of the methods applied by us to assess CD36
translocation, including two-photon microscopy, clearly indi-
cated enhanced CD36 translocation in response to A23187 or
thapsigargin. The inability of these agents to activate AMPK
indicates that Ca2-induced CD36 translocation and also
GLUT4 translocation occur independently from AMPK signal-
ing. Furthermore, both Ca2-induced GLUT4 translocation
and CD36 translocation are sensitive to inhibition by STO-609
and KN93, pointing to the involvement of CaMKK/CaMKs.
A positive control in our translocation studies was the
translocation of both GLUT4 and CD36 in response to AMPK
activation by oligomycin, in agreement with previous studies
Fig. 6. Effects of AMPK inhibitors on sub-
strate uptake into cardiomyocytes treated
with Ca2-elevating and/or AMPK-activat-
ing agents. Cardiomyocytes were incubated
for 15 min in the absence (C) or presence of
adenine 9--D-arabinofuranoside (Ara-A; 3
mM) or compound C (50 M) for 15 min
prior to a 15-min incubation with A23 and/
or AICAR, and subsequent assessment of
[3H]glucose and [14C]palmitate uptake (A)
and AMPK and ACC phosphorylation (B).
Values are displayed as means 	 SE (n 
5). *Vs. control; ^vs. Oli; $vs. AICAR; ^^vs.
A23/AICAR (P 
 0.05).
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(32, 34). AMPK-mediated transporter translocation has been
found to be dependent on phosphorylation-mediated inhibition
of AS160 (18, 39), and in agreement, oligomycin treatment
resulted in AS160 phosphorylation (Fig. 5A). Surprisingly,
activation of Ca2 signaling does not lead to phosphorylation
of AS160, suggesting that AS160 does not regulate Ca2-
induced transporter translocation. Perhaps Rab GTPase-acti-
vating proteins other than AS160 (i.e., its homologue
TBC1D1) are involved herein.
Besides the fact that the cell surface biotinylation experi-
ments provide evidence for Ca2-induced GLUT4 and CD36
translocation, these experiments also indicate that both trans-
porters have properly arrived at the cell surface and have
access to the extracellular milieu. This indicates that Ca2
signaling is involved not only in the vesicle-mediated GLUT4
and CD36 translocation process but also in the subsequent
fusion of the GLUT4- and CD36-containing vesicles with the
plasma membrane.
Activation of Ca2 Signaling is Not Sufficient to Stimulate
Glucose and LCFA Uptake
In contrast to the parallel increases in AMPK-mediated
substrate transporter translocation and AMPK-mediated sub-
strate uptake, Ca2-induced GLUT4 and CD36 translocation
was not accompanied by increases in glucose and LCFA
uptake. A likely explanation for these findings is that substrate
transporter translocation (including subsequent fusion with the
plasma membrane) is necessary but not sufficient for a given
stimulus to increase substrate uptake. Hence, once they arrive
at the cell surface, substrate transporters may need an addi-
tional activation step to become fully functional in substrate
uptake. In the case of AMPK signaling, this signaling route
might then be involved in both transporter translocation and
cell surface activation of the transporters. In contrast, Ca2
signaling appears to be involved only in the first step, the
translocation, and ineffective in further cell surface activation.
Evidence for such a two-step process in the stimulation of
substrate transport has been reported previously in adipocytes
as the inability of phosphatidylinositol-3,4,5-trisphosphate
(PIP3) to stimulate glucose uptake into these cells despite a
successful translocation of GLUT4 to the plasma membrane
(41). These latter findings indicate that PIP3 [the main product
of insulin-stimulated phosphatidylinositol-3 kinase (PI3K) ac-
tivation] is involved in insulin-stimulated GLUT4 transloca-
tion, but the GLUT4 activation step required for insulin-
stimulated glucose uptake is mediated by another, perhaps
PI3K-independent, factor.
Similarly, in AMPK-mediated substrate uptake, the cell
surface activation step would require different downstream
mechanisms of AMPK compared with the translocation step.
Specifically, whereas phosphorylation of AS160 (or TBC1D1)
by AMPK is involved in the regulation of GLUT4 and CD36
translocation (29, 39), we do not necessarily expect AS160/
TBC1D1 to be involved in cell surface transporter activation at
the cell surface since the Rab GTPase activity of both proteins
is tightly connected to vesicular trafficking (13).
We can only speculate about the mechanism of AMPK-
mediated transporter activation at the cell surface. This activa-
tion step might involve a signaling-induced phosphorylation of
each of the transporters individually. However, evidence for
phosphorylation of GLUT4 or of CD36 to regulate transport
activity is scarce. For CD36, merely ectophosphorylation was
reported (19), whereas for GLUT4, a study in adipocytes
showed that GLUT4 phosphorylation is inversely correlated
with glucose uptake in response to insulin stimulation (5).
Alternatively, both GLUT4 and CD36 might be activated in
another combined event. For instance, GLUT4 and CD36 may
translocate simultaneously to sarcolemmal regions that are
nonfunctional in substrate uptake and then laterally migrate
through the sarcolemma to a subdomain that is functional in
Fig. 7. Putative mechanism of the synergistic
effect of Ca2 and AMPK signaling on car-
diac glucose and fatty acid uptake. Contrac-
tion as induced by an action potential (AP)
leads to activation of AMPK. Both contrac-
tion-induced AMPK activation and a supra-
physiological influx of Ca2 into cardiomy-
ocytes (e.g., induced by A23187) trigger
translocation of GLUT4 and CD36 from
separate AMPK-responsive and Ca2 sig-
naling-responsive endosomal subcompart-
ments to the sarcolemma. AS160 is involved
in AMPK-mediated GLUT4/CD36 translo-
cation but not in Ca2-induced transporter
translocation. Both transporters arrive at the
sarcolemma in an inactive state (depicted by
a light gray fill color). Then, both transport-
ers need an activation step [possibly lateral
movement through the bilayer towards a
specific membrane domain (depicted as a
black membrane area) to become functional
in substrate uptake (depicted by a dark gray
fill color)]. This latter step is dependent on
AMPK activation. Hence, whereas AMPK-
recruited transporters do not require addi-
tional signaling pathways to effectuate trans-
location into enhanced substrate uptake,
[Ca2]i-recruited transporters depend on ad-
ditional AMPK activation to become functional.
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substrate uptake. Such sarcolemmal subdomains might include
caveolae, which have been demonstrated to be necessary for
LCFA uptake, at least in adipocytes (36). Furthermore, protein-
protein interactions could be involved in sarcolemmal activa-
tion of both transporters. In the case of GLUT4, reciprocal
binding of GAPDH and hexokinase II has been shown to
modulate GLUT4 activity (49).
Combined Activation of Ca2 Signaling and AMPK
Signaling Synergistically Stimulates Glucose and LCFA
Uptake in an AMPK-Sensitive Manner
One major observation in this study is that activation of
Ca2 signaling, by itself unsuccessful in stimulating glucose
and LCFA uptake into cardiomyocytes, substantially stimu-
lated cardiac substrate uptake upon coactivation of AMPK
signaling. Hence, Ca2 signaling is dependent on separate
coactivation of AMPK signaling to stimulate cardiac substrate
uptake (illustrated in Fig. 7). In view of the ability of Ca2
signaling to induce both GLUT4 and CD36 to translocate to the
sarcolemma, once they have arrived at the cell surface, both
transporters might undergo subsequent activation by AMPK
signaling. The observation that pharmacological AMPK inhib-
itors entirely block substrate uptake induced by combined
activation of Ca2 and AMPK signaling provides support that
activation of Ca2-recruited transporters is indeed due to
AMPK and not to an off-target effect of these stimuli.
The findings of this study point toward a gap in our knowl-
edge of the role of Ca2 and CaMKs on contraction stimulation
of cardiac substrate uptake. Our findings revealed that upon an
exaggerated rise in [Ca2]i by pharmacological agents, activa-
tion of CaMKs will induce both GLUT4 and CD36 transloca-
tion. However, contraction stimulation did not activate Ca2
signaling, at least not within the observation time (several
minutes). Perhaps Ca2-induced/CaMK-mediated transporter
translocation might gain importance during pathological Ca2
overload conditions (17), as mimicked by thapsigargin or
A23187 treatment. Under such pathological conditions, AMPK
activity would not be expected to be impaired and thus amply
sufficient to mediate cell surface transporter activation. Then,
Ca2-induced transporter translocation can be effectuated into
increased substrate uptake. Together, the present findings point
toward the hypothetical presence of separate GLUT4/CD36-
containing subcompartments within the endosomes specifically
responsive to a rise in [Ca2]i next to the AMPK-responsive
storage compartments for these transporters. The recruitment
of transporters from these Ca2-responsive storage compart-
ments might be restricted to emergency situations (like hypoxia
and fight/flight response) to meet the excessive metabolic
demands of the heart in such conditions.
Yet the basal activity of CaMKs in the heart or the changes
in activation of CaMKs on a millisecond time scale are not yet
known. Similarly to Ca2 waves that activate CaMK signaling,
AMPK activation status might also fluctuate on the millisecond
time scale. Expectedly, there would be some delay to the
CaMK signaling, because the increased energy demand (that is
sensed by AMPK through changes in adenine nucleotide lev-
els) evolves from the Ca2-induced cardiomyocyte contrac-
tion. Thus, we could speculate about Ca2/CaMK signaling
preparing the cardiomyocyte for substrate uptake during con-
traction by inducing transporter translocation, which in the
case of actual energy requirement is finalized by AMPK into
substrate uptake to refill cellular energy. At present, it is not
possible for us to determine CaMK and AMPK signaling
changes occurring at such a rapid pace. In conclusion, we
cannot exclude a possible millisecond action of CaMKs on
transporter translocation under normal physiological condi-
tions.
Finally, identification of the proteins functioning down-
stream of CaMKs in Ca2-induced translocation of GLUT4
and CD36 might provide novel targets to influence cardiac
substrate uptake.
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Muñoz P, Gumà A, Testar X, Palacín M, Blasi J, Fischer Y. Regulation
of glucose transport, and glucose transporters expression and trafficking in
the heart: studies in cardiac myocytes. Am J Cardiol 80: 65A–76A, 1997.
E236 CALCIUM SIGNALING AND CARDIAC SUBSTRATE UPTAKE
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00655.2013 • www.ajpendo.org
Downloaded from journals.physiology.org/journal/ajpendo at Universiteit Maastricht (137.120.144.057) on September 15, 2021.
